Tuesday, 2 December 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 02 December 2025
News

Who's won 2025's last PBS listings?

Posted 2 December 2025 AM

The last round of PBS listings for the year have dropped with seven drugs nabbing the final reimbursements of 2025, including a next-gen PD-1 inhibitor.

Dr Reddy's immunotherapy Zytorvi was recommended by PBAC in July and is the first and only targeted treatment for nasopharyngeal cancer (NPC), a rare and aggressive form of head and neck cancer. About 200 Australians are diagnosed with NPC each year, most predominantly men over the age of 40.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (16)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.